Pediatric IPEX-Associated Dermatitis Responds To Dupilumab: Evidence from Skin Transcriptomics and Immune Profiling.

Key Points

• To evaluate the effectiveness of dupilumab in treating refractory dermatitis associated with IPEX.
• Analyzed skin transcriptomics in pediatric subjects.
• Profiled immune responses focusing on Th1, Th2, Treg, and Th3 cells.
• Investigated treatment effects before and after dupilumab administration.
• Dupilumab significantly reduced Th1 and Th2 inflammation.
• Treatment promoted regulatory responses mediated by Treg and Th3 cells.
• Patients exhibited improved clinical outcomes post-treatment.